ABD’li ila\u00e7 firmas\u0131 Merck, korona vir\u00fcs\u00fcn etkilerini ve vir\u00fcse ba\u011fl\u0131 \u00f6l\u00fcm oranlar\u0131n\u0131 azaltan ilk hap formundaki ilac\u0131 geli\u015ftirdi\u011fini a\u00e7\u0131klad\u0131. Merck, Molnupiravir ad\u0131n\u0131 verdi\u011fi ilac\u0131n\u0131n, enfeksiyonun erken evresindeki ki\u015filerde hastaneye yat\u0131\u015f ve \u00f6l\u00fcm oranlar\u0131n\u0131 y\u00fczde 50 oran\u0131nda azaltt\u0131\u011f\u0131n\u0131 belirterek, ilac\u0131n ABD ve di\u011fer \u00fclkelerde kullan\u0131m\u0131 i\u00e7in ABD G\u0131da ve \u0130la\u00e7 Dairesi’ne (FDA) ba\u015fvuraca\u011f\u0131n\u0131 aktard\u0131.<\/p>\n\n\n\n
Merck ve biyoteknoloji firmas\u0131 orta\u011f\u0131 Ridgeback Biotherapeutics’un y\u00fcr\u00fctt\u00fc\u011f\u00fc ara\u015ft\u0131rmada, Covid-19’u a\u011f\u0131r ge\u00e7irme riski bulunan 775 yeti\u015fkin aras\u0131ndan enfeksiyonun erken evrelerinde Molnupiravir’i alanlarda hastaneye yat\u0131\u015f ve \u00f6l\u00fcm oranlar\u0131nda yar\u0131 yar\u0131ya d\u00fc\u015f\u00fc\u015f kaydedildi\u011fi belirtildi.<\/p>\n\n\n\n
Ara\u015ft\u0131rmaya g\u00f6re, etkin madde i\u00e7ermeyen plasebo alan hastalar\u0131n y\u00fczde 14,1’inin 30 g\u00fcn sonunda hastaneye kald\u0131r\u0131ld\u0131\u011f\u0131 veya hayat\u0131n\u0131 kaydetti\u011fi bildirilirken, korona vir\u00fcs\u00fcn \u00e7o\u011falmas\u0131n\u0131 sa\u011flayan enzime m\u00fcdahale eden Molnupiravir’i alan hastalarda ise bu oran\u0131n y\u00fczde 7,3 oldu\u011fu kaydedildi.<\/p>\n\n\n\n
Molnupiravir alan deney grubunda 30 g\u00fcnl\u00fck s\u00fcre sonras\u0131nda can kayb\u0131 ya\u015fanmad\u0131<\/strong><\/p>\n\n\n\n Merck taraf\u0131ndan yap\u0131lan a\u00e7\u0131klamada, Molnupiravir alan deney grubunda 30 g\u00fcnl\u00fck s\u00fcre sonras\u0131nda can kayb\u0131 ya\u015fanmad\u0131\u011f\u0131 ancak plasebo alan deney grubunda ise 8 ki\u015finin hayat\u0131n\u0131 kaybetti\u011fi belirtildi. Son a\u015fama deneylere bin 500’den fazla ki\u015finin kat\u0131lmas\u0131 planlan\u0131yor<\/strong><\/p>\n\n\n\n Merck’in ilaca dair son a\u015fama deneylerine bin 500’den fazla hastan\u0131n kat\u0131lmas\u0131 planlan\u0131rken, \u00e7al\u0131\u015fmay\u0131 takip eden ba\u011f\u0131ms\u0131z t\u0131p uzmanlar\u0131, \u00f6n sonu\u00e7lar\u0131n g\u00fc\u00e7l\u00fc olmas\u0131 nedeniyle deneylerin durdurulmas\u0131n\u0131 \u00f6nerdi. Deneylere Latin Amerika, Avrupa ve Afrika’dan hastalar kat\u0131ld\u0131.<\/p>\n\n\n\n ABD 1,7 milyon doz sat\u0131n almay\u0131 planl\u0131yor<\/strong><\/p>\n\n\n\n Merck yetkilileri, \u00f6n\u00fcm\u00fczdeki g\u00fcnlerde ilac\u0131n yayg\u0131n kullan\u0131m\u0131n\u0131n ba\u015flat\u0131lmas\u0131na y\u00f6nelik de\u011ferlendirme i\u00e7in ABD G\u0131da ve \u0130la\u00e7 Dairesi’ne (FDA) ba\u015fvurulaca\u011f\u0131n\u0131 s\u00f6yledi. ABD h\u00fck\u00fcmeti, ilac\u0131n FDA onay\u0131 almas\u0131 durumunda 1 milyon 700 bin doz sat\u0131n al\u0131naca\u011f\u0131na y\u00f6nelik taahh\u00fctte bulundu.<\/p>\n\n\n\n \u0130ngiltere ilaca ilgi g\u00f6steriyor<\/strong><\/p>\n\n\n\n \u0130ngiltere’nin Antiviraller G\u00f6rev G\u00fcc\u00fc Ba\u015fkan\u0131 Eddie Gray, Merck’in Covid-19’a kar\u015f\u0131 geli\u015ftirdi\u011fi hap formundaki ilaca \u0130ngiltere’nin ilgisi oldu\u011funu ima etti. Gray kat\u0131ld\u0131\u011f\u0131 \u00e7evrimi\u00e7i bir toplant\u0131da, ila\u00e7 hakk\u0131nda a\u00e7\u0131klamada bulunurken, “Mevcut t\u00fcm se\u00e7eneklere yak\u0131ndan bakmakla ilgileniyoruz” dedi.<\/p>\n\n\n\n Merck’in bula\u015f\u0131c\u0131 hastal\u0131klardan sorumlu Ba\u015fkan Yard\u0131mc\u0131s\u0131 Daria Hazuda’n\u0131n da oldu\u011fu toplant\u0131da a\u00e7\u0131klamalarda bulunan Gray, kat\u0131ld\u0131\u011f\u0131 toplant\u0131y\u0131 kastederek, “Bug\u00fcn burada olmay\u0131 se\u00e7tim” ifadelerini kullandi. Gray, ilaca y\u00f6nelik do\u011frudan bir yorumda bulundu\u011funu reddederken, “A\u015fama 3 verilerinin ortaya \u00e7\u0131kmas\u0131 bu t\u00fcr s\u00fcre\u00e7leri h\u0131zland\u0131rma e\u011filimindedir, ancak size kesin bir tarih veremem” dedi.<\/p>\n","protected":false},"excerpt":{"rendered":" ABD’li ila\u00e7 firmas\u0131 Merck, Covid-19’un a\u011f\u0131r etkilerini ve vir\u00fcs kaynakl\u0131 \u00f6l\u00fcm oranlar\u0131n\u0131 y\u00fczde 50 oran\u0131nda azaltan hap formundaki ilk ilac\u0131 geli\u015ftirdi\u011fini a\u00e7\u0131klad\u0131. ABD’li ila\u00e7 firmas\u0131 Merck, korona vir\u00fcs\u00fcn etkilerini ve vir\u00fcse ba\u011fl\u0131 \u00f6l\u00fcm oranlar\u0131n\u0131 azaltan ilk hap formundaki ilac\u0131 geli\u015ftirdi\u011fini a\u00e7\u0131klad\u0131. Merck, Molnupiravir ad\u0131n\u0131 verdi\u011fi ilac\u0131n\u0131n, enfeksiyonun erken evresindeki ki\u015filerde hastaneye yat\u0131\u015f ve \u00f6l\u00fcm oranlar\u0131n\u0131 […]<\/p>\n","protected":false},"author":1,"featured_media":1573603,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1573602","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-gundem"],"_links":{"self":[{"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=\/wp\/v2\/posts\/1573602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1573602"}],"version-history":[{"count":0,"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=\/wp\/v2\/posts\/1573602\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=\/wp\/v2\/media\/1573603"}],"wp:attachment":[{"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1573602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1573602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.erzhaber.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1573602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Merck ara\u015ft\u0131rma grubundan Ba\u015fkan Yard\u0131mc\u0131s\u0131 Dr. Dean Li ise yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, “Bu klinik deneyde ilac\u0131n g\u00f6sterdi\u011fi etki, beklentilerimi a\u015ft\u0131” ifadelerini kullanarak, “Hastaneyeyat\u0131\u015f ve \u00f6l\u00fcm oranlar\u0131nda y\u00fczde 50’lik azalma, az\u0131msanamayacak bir klinik etki anlam\u0131na geliyor” dedi.<\/p>\n\n\n\n